Could Pfizer Choose To Consciously Stay Coupled?
The end of the Pfizer/Allergan merger dream brought the Pfizer break up decision timeline back to the fourth quarter of 2016. Since Ian Read first floated the idea back in 2011 it has been regarded as question of when, not if, but this has now been challenged by one intrepid analyst.
You may also be interested in...
Pfizer, Merck KGaA, Novo Nordisk, Shire, Allergan and Teva are among those pharmaceutical majors still to report their 2Q results. Scrip considers what’s in store.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.